EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

19 July 2013
EMA/CVMP/322884/2013
Committee for Medicinal Products for Veterinary Use

Summary of opinion[1] (post-authorisation)

Cerenia

International non-proprietary name (INN): Maropitant

On 18 July 2013, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted an opinion[2] recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Cerenia. The marketing authorisation holder for this veterinary medicinal product is Zoetis Belgium S.A.

The change agreed by the CVMP concerns an additional claim for the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the μ-opiate receptor agonist morphine.

Detailed conditions for the use of this product will be described in the updated summary of product characteristics (SPC) which will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8447
E-mail info@ema.europa.eu **Website** www.ema.europa.eu